Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Oct;343(1):72-81.
doi: 10.1124/jpet.112.194308. Epub 2012 Jun 28.

Roles of μ-opioid receptors and nociceptin/orphanin FQ peptide receptors in buprenorphine-induced physiological responses in primates

Colette M Cremeans  1 , Erin Gruley, Donald J Kyle, Mei-Chuan Ko
Affiliations

Roles of μ-opioid receptors and nociceptin/orphanin FQ peptide receptors in buprenorphine-induced physiological responses in primates

Colette M Cremeans et al. J Pharmacol Exp Ther. 2012 Oct.

Abstract

Buprenorphine is known as a μ-opioid peptide (MOP) receptor agonist, but its antinociception is compromised by the activation of nociceptin/orphanin FQ peptide (NOP) receptors in rodents. The aim of this study was to investigate the roles of MOP and NOP receptors in regulating buprenorphine-induced physiological responses in primates (rhesus monkeys). The effects of MOP antagonist (naltrexone), NOP antagonist [(±)-1-[(3R*,4R*)-1-(cyclooctylmethyl)-3-(hydroxymethyl)-4-piperidinyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one (J-113397)], and NOP agonists [(1S,3aS)-8-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4.5] decan-4-one (Ro 64-6198) and 3-endo-8-[bis(2-methylphenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol (SCH 221510)] on buprenorphine were studied in three functional assays for measuring analgesia, respiratory depression, and itch in primates. Over the dose range of 0.01 to 0.1 mg/kg, buprenorphine dose-dependently produced antinociception, respiratory depression, and itch/scratching responses, and there was a ceiling effect at higher doses (0.1-1 mg/kg). Naltrexone (0.03 mg/kg) produced similar degrees of rightward shifts of buprenorphine's dose-response curves for all three endpoints. Mean pK(B) values of naltrexone (8.1-8.3) confirmed that MOP receptors mediated mainly buprenorphine-induced antinociception, respiratory depression, and itch/scratching. In contrast, J-113397 (0.1 mg/kg) did not change buprenorphine-induced physiological responses, indicating that there were no functional NOP receptors in buprenorphine-induced effects. More importantly, both NOP agonists, Ro 64-6198 and SCH 221510, enhanced buprenorphine-induced antinociception without respiratory depression and itch/ scratching. The dose-addition analysis revealed that buprenorphine in combination with the NOP agonist synergistically produced antinociceptive effects. These findings provided functional evidence that the activation of NOP receptors did not attenuate buprenorphine-induced antinociception in primates; instead, the coactivation of MOP and NOP receptors produced synergistic antinociception without other side effects. This study strongly supports the therapeutic potential of mixed MOP/NOP agonists as innovative analgesics.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Antinociceptive effects of subcutaneously administered buprenorphine over a wide dose range against an acute noxious stimulus (50°C water) in primates. A, low doses. B, high doses. Each data point represents a mean ± S.E.M. (n = 6). *, a significant difference from the vehicle condition from the time point 30 min to the corresponding time point for each dose (p < 0.05). The same data of buprenorphine (0.1 mg/kg) are presented in A (●) and B (▼) for comparison with other doses.
Fig. 2.
Fig. 2.
Respiratory depressant effects of intramuscularly administered buprenorphine over a wide dose range in primates breathing air mixed with 5% CO2. A and C, f values for low doses (A) and high doses (C) of buprenorphine. B and D, Ve values for low doses (B) and high doses (D) of buprenorphine. Each data point represents a mean ± S.E.M. (n = 6). *, a significant difference from the vehicle condition for all time points (p < 0.05). The same data of buprenorphine (0.1 mg/kg) are presented in A and B (●) and C and D ▼) for comparison with other doses.
Fig. 3.
Fig. 3.
Itch/scratching eliciting effects of intramuscularly administered buprenorphine over a wide dose range in primates. Each data point represents a mean ± S.E.M. (n = 6). *, a significant difference from the vehicle condition from the time point 30 min to the corresponding time point for each dose (p < 0.05).
Fig. 4.
Fig. 4.
Effects of MOP and NOP antagonists on buprenorphine-induced antinociception in primates. The MOP antagonist naltrexone (0.03 mg/kg) or the NOP antagonist J-113397 (0.1 mg/kg) was administered subcutaneously 15 min before determination of buprenorphine's dose-response curve. Each data point represents a mean ± S.E.M. (n = 6).
Fig. 5.
Fig. 5.
Effects of MOP and NOP antagonists on buprenorphine-induced respiratory depression in primates. A single dose of the MOP antagonist naltrexone (0.03 mg/kg) or the NOP antagonist J-113397 (0.1 mg/kg) was administered intramuscularly 30 min before administration of the first dose of buprenorphine. Data represent the changes of both parameters, ƒ (A) and VE (B), in primates breathing air mixed with 5% CO2. Each data point represents a mean ± S.E.M. (n = 6).
Fig. 6.
Fig. 6.
Effects of MOP and NOP antagonists on buprenorphine-induced itch/scratching activity in primates. A single dose of the MOP antagonist naltrexone (0.03 mg/kg) or the NOP antagonist J-113397 (0.1 mg/kg) was administered intramuscularly 15 min before determination of buprenorphine's dose-response curve. Each data point represents a mean ± S.E.M. (n = 6).
Fig. 7.
Fig. 7.
Effects of the NOP agonists Ro 64-6198 and SCH 221510 in combination with buprenorphine on antinociception, respiratory depression, and itch/scratching responses. A and B, dose-response curves for antinociception produced by buprenorphine alone and in mixtures with either Ro 64-6198 (A) or SCH 221510 (B). C and D, dose-response curves for respiratory depression produced by buprenorphine alone and in the same dose combination, as presented in A and B, with either Ro 64-6198 (C) or SCH 221510 (D). E and F, dose-response curves for itch/scratching responses elicited by buprenorphine alone or in the same dose combination, as presented in A and B, with either Ro 64-6198 (E) or SCH 221510 (F). All drugs were administered intramuscularly in the same subjects. Each data point represents a mean ± S.E.M. (n = 6). *, a significant difference from the dosing condition of buprenorphine (0.003 mg/kg) alone (p < 0.05).
Fig. 8.
Fig. 8.
Effects of the NOP agonists Ro 64-6198 and SCH 221510 in combination with buprenorphine on antinociceptive effects against 50°C water. Isobolograms for the mixture of buprenorphine with either Ro 64-6198-induced antinociception (A) or SCH 221510-induced antinociception (B) are displayed. . Each data point represents a mean ± S.E.M. (n = 6). See Tables 2 and 3 and Data Analysis for other details.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bailey PL, Rhondeau S, Schafer PG, Lu JK, Timmins BS, Foster W, Pace NL, Stanley TH. (1993) Dose-response pharmacology of intrathecal morphine in human volunteers. Anesthesiology 79:49–59; discussion 25A - PubMed
    1. Butelman ER, France CP, Woods JH. (1993) Apparent pA2 analysis on the respiratory depressant effects of alfentanil, etonitazene, ethylketocyclazocine (EKC) and Mr2033 in rhesus monkeys. J Pharmacol Exp Ther 264:145–151 - PubMed
    1. Calo' G, Guerrini R, Rizzi A, Salvadori S, Regoli D. (2000) Pharmacology of nociceptin and its receptor: a novel therapeutic target. Br J Pharmacol 129:1261–1283 - PMC - PubMed
    1. Cami-Kobeci G, Polgar WE, Khroyan TV, Toll L, Husbands SM. (2011) Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine. J Med Chem 54:6531–6537 - PMC - PubMed
    1. Clark MJ, Furman CA, Gilson TD, Traynor JR. (2006) Comparison of the relative efficacy and potency of μ-opioid agonists to activate Gαi/o proteins containing a pertussis toxin-insensitive mutation. J Pharmacol Exp Ther 317:858–864 - PubMed

Publication types